1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,440 | 4,740 | 20.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.12. | Elicio reports promising cancer vaccine trial results | 1 | Investing.com | ||
| 12.12. | Elicio meldet vielversprechende Ergebnisse der Krebsimpfstoff-Studie | 2 | Investing.com Deutsch | ||
| 12.12. | Elicio Therapeutics Inc.: Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 | 82 | GlobeNewswire (Europe) | Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population Strong correlation observed between mRFS... ► Artikel lesen | |
| 12.12. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12. | Elicio completes phase 2 enrollment for cancer vaccine | 1 | Investing.com | ||
| 03.12. | Elicio schließt Patientenrekrutierung für Phase-2-Studie eines Krebsimpfstoffs ab | 1 | Investing.com Deutsch | ||
| 03.12. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment | 79 | GlobeNewswire (Europe) | BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 03.12. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.11. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Elicio Therapeutics GAAP EPS of -$1.39 | 1 | Seeking Alpha | ||
| 13.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 80 | GlobeNewswire (Europe) | AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for... ► Artikel lesen | |
| 07.11. | Elicio reports promising Phase 1 cancer vaccine trial results | 1 | Investing.com | ||
| 07.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting | 42 | GlobeNewswire (Europe) | Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival... ► Artikel lesen | |
| 07.11. | Elicio Therapeutics adjourns annual meeting due to lack of quorum | 1 | Investing.com | ||
| 07.11. | Elicio Therapeutics vertagt Jahreshauptversammlung aufgrund fehlender Beschlussfähigkeit | - | Investing.com Deutsch | ||
| 07.11. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.10. | Elicio Therapeutics Inc.: Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit | 1 | GlobeNewswire (USA) | ||
| 30.10. | Elicio Therapeutics stock rated Buy with $9 target by Jones Trading | 1 | Investing.com | ||
| 17.10. | Elicio Therapeutics announces new CFO and accounting officer | 1 | Investing.com | ||
| 17.10. | Elicio Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| NANOREPRO | 1,340 | +3,08 % | NanoRepro Aktie: Alles im Blick? | Die NanoRepro AG, ein führender Entwickler medizinischer Selbsttests, zeigt sich trotz wirtschaftlicher Herausforderungen widerstandsfähig. Am 09. November 2024 notierte die Aktie bei 1,64 EUR, unverändert... ► Artikel lesen | |
| OCUGEN | 0,718 | -2,45 % | Ocugen: Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 40,570 | +0,07 % | AKTIEN IM FOKUS: Novo Nordisk sacken nach Daten ab - Gerresheimer schwach | KOPENHAGEN/FRANKFURT/NEW YORK (dpa-AFX) - Enttäuschende Studienergebnisse haben dem dänischen Pharmakonzern Novo Nordisk am Freitag den höchsten Kursverlust in seiner Geschichte eingebrockt. Die Papiere... ► Artikel lesen | |
| SCORPIUS | 0,330 | -12,81 % | Scorpius Holdings, Inc. - S-1, General form for registration of securities | ||
| COSCIENS BIOPHARMA | 2,700 | +8,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs |
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,158 | -1,59 % | BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next? | ||
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,420 | 0,00 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| VAXART | 0,600 | +1,61 % | Vaxart, Inc.: Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's... ► Artikel lesen | |
| IBIO | 3,515 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,070 | -0,13 % | Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom... ► Artikel lesen | |
| ALDEYRA | 4,586 | -1,61 % | Aldeyra Therapeutics Aktie: Umsatzprognosen klar übertroffen! | Die Aldeyra Therapeutics Aktie verzeichnete am 23. November einen bemerkenswerten Handelstag mit einem Kursanstieg von 1,73 Prozent auf 4,70 EUR. Der Biotech-Konzern, der sich auf die Entwicklung von... ► Artikel lesen | |
| MANNKIND | 6,700 | +2,35 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.
